Bladder cancer drug combo trial stalls early
NCT ID NCT01382706
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This small phase II study tested whether combining the chemotherapy drug docetaxel with the targeted therapy lapatinib could help patients with advanced bladder cancer that had already been treated with platinum-based chemo. Only 15 people enrolled before the study was terminated early, so we have very little data on how well it worked or what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel and lapatinib
What this could lead to
If successful, this combination could offer a second-line treatment option for advanced bladder cancer patients who have already tried platinum-based chemotherapy.
What could go wrong
The trial was terminated early with only 15 participants, so results are very limited. It is unclear if the combination is effective or safe enough to pursue further.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.